CORT Corcept Therapeutics Incorporated

16.11
-1.08  -6%
Previous Close 17.19
Open 16.98
Price To Book 7.16
Market Cap 1860250666
Shares 115,471,798
Volume 2,840,580
Short Ratio
Av. Daily Volume 1,436,599

NewsSee all news

  1. Biotech Companies in the News
  2. Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome
  3. IBD 50 Stocks To Watch: Corcept Expected To Pick Up Growth In 2019
  4. Today's Research Reports on Trending Tickers: MYOS RENS Technology and Corcept Therapeutics
  5. Here's Why Corcept Therapeutics Surged Today

SEC filingsSee all SEC filings

  1. 8-K - Current report 181191340
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181155012
  3. 8-K - Current report 181153856
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181005538
  5. 8-K - Current report 181005118

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved February 17, 2012.
Corlux - Korlym
Cushing's Syndrome
Phase 2 ongoing.
Mifepristone plus enzalutamide
Castration-resistant prostate cancer (CRPC)
Phase 1/2 data released December 10, 2016 - 4/21 partial responses.
Mifepristone in combination with eribulin
Cancer - triple-negative breast cancer
Phase 2 pancreatic data due by end of 2018.
Relacorilant
Solid tumors - cancer
Phase 3 commencement of enrolment announced November 19, 2018.
Relacorilant
Cushing’s syndrome
Phase 2 trial to commence later in 2018.
Relacorilant plus Abraxane
Ovarian cancer

Latest News

  1. Biotech Companies in the News
  2. Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome
  3. IBD 50 Stocks To Watch: Corcept Expected To Pick Up Growth In 2019
  4. Today's Research Reports on Trending Tickers: MYOS RENS Technology and Corcept Therapeutics
  5. Here's Why Corcept Therapeutics Surged Today
  6. Here's Why Corcept Therapeutics Rose 18.6% in November
  7. Report: Exploring Fundamental Drivers Behind Tesla, Nordson, Paycom Software, PDL BioPharma, Corcept Therapeutics, and Willis Towers Watson Public — New Horizons, Emerging Trends, and Upcoming Developments
  8. What You Must Know About Corcept Therapeutics Incorporated’s (NASDAQ:CORT) Financial Strength
  9. Corcept Initiates Phase III Study for Cushing's Syndrome
  10. Corcept Therapeutics Announces First Patient Dosed in Phase 3 Trial of Relacorilant to Treat Patients with Cushing’s Syndrome
  11. Edited Transcript of CORT earnings conference call or presentation 1-Nov-18 9:00pm GMT
  12. Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates
  13. Corcept Therapeutics (CORT) Meets Q3 Earnings Estimates
  14. Corcept: 3Q Earnings Snapshot
  15. Corcept Therapeutics Announces Third Quarter 2018 Financial Results and Provides Corporate Update
  16. Is Corcept Therapeutics Incorporated’s (NASDAQ:CORT) CEO Incentives Align With Yours?
  17. Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
  18. Judge Denies Teva Pharmaceuticals’ Motion to Dismiss Corcept Therapeutics’ Allegations of Patent Infringement
  19. Report: Exploring Fundamental Drivers Behind Corcept Therapeutics, News Corporation, Nightstar Therapeutics PLC Sponsored ADR, Rudolph Technologies, Applied Optoelectronics, and United Rentals — New Horizons, Emerging Trends, and Upcoming Developments
  20. Should You Be Holding Corcept Therapeutics Incorporated (NASDAQ:CORT) Right Now?

SEC Filings

  1. 8-K - Current report 181191340
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181155012
  3. 8-K - Current report 181153856
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181005538
  5. 8-K - Current report 181005118
  6. 8-K - Current report 18998058
  7. 8-K - Current report 18878169
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 18816086
  9. 8-K - Current report 18814625
  10. DEF 14A - Other definitive proxy statements 18771486